Anti-Müllerian hormone (AMH) testing has become an increasingly common part of fertility assessments, and many women encounter it either through a healthcare provider’s recommendation or through direct-to-consumer testing services. For women over 35, AMH often comes with significant emotional weight — a number that feels like it might tell a definitive story about fertility prospects.
The reality of what AMH can and cannot tell you is more nuanced than that number alone suggests. Understanding what AMH actually measures, how it fits into a broader fertility assessment, and its limitations can help situate this one data point within a more complete picture.
What AMH Measures — and What It Doesn’t
AMH is a hormone produced by small follicles in the ovaries. Its level in the blood is considered a marker of ovarian reserve — essentially, the quantity of eggs remaining in the ovaries. Unlike hormones that fluctuate throughout the menstrual cycle (such as FSH and estradiol), AMH is relatively stable across cycle days, making it a convenient test to schedule.
Importantly, AMH reflects quantity, not quality. Egg quality — which is generally considered the more significant factor in conception and healthy pregnancy rates after 35 — cannot currently be assessed by any blood test. AMH tells you approximately how many eggs are available, but it does not tell you whether those eggs are chromosomally normal or likely to result in a successful pregnancy. For more context on fertility factors after 35, understanding how cycle changes relate to fertility can be a helpful companion resource.
What the Research Shows About AMH and Age
Research published through the National Library of Medicine consistently shows that AMH levels decline with age, reflecting the natural reduction in ovarian reserve over time. This decline typically accelerates in the late 30s and through the 40s. Population-based reference ranges have been developed for AMH by age group, though there is wide natural variation — a woman in her late 30s with a relatively low AMH for her age may still conceive, while high AMH does not guarantee ease of conception.
Studies examining the relationship between AMH levels and natural conception rates in women trying to conceive have found that, at the population level, lower AMH is associated with modestly reduced conception probabilities over a given time period. However, the predictive value of AMH for an individual woman’s conception prospects is limited — particularly for women who are not pursuing IVF, where ovarian reserve is a more directly relevant factor in treatment planning.
AMH in the Context of Fertility Evaluation
AMH is one component of a broader ovarian reserve assessment, which typically also includes a transvaginal ultrasound to count antral follicles (the antral follicle count, or AFC) and, in some cases, cycle day 2–3 FSH and estradiol levels. Together, these measures provide a more complete picture of ovarian reserve than any single test alone.
AMH and IVF Planning
AMH is most directly useful in the context of IVF treatment planning, where it helps clinicians anticipate how the ovaries are likely to respond to hormonal stimulation. Lower AMH may suggest a reduced response to stimulation medications, influencing dosing decisions and expectations for the number of eggs retrieved. Even with lower AMH, IVF outcomes vary widely depending on many factors, including egg quality and broader health considerations.
AMH and Natural Conception
For women trying to conceive naturally, AMH’s predictive value for individual outcomes is more limited. Studies have not found that AMH is a strong predictor of whether a woman will conceive naturally over a given period. A woman with lower-than-average AMH for her age is not necessarily unable to conceive without assistance. Understanding the role of progesterone and other hormones in fertility alongside ovarian reserve information can provide more complete context.
The Emotional Weight of AMH Numbers
For many women who receive AMH results — particularly those below average for their age group — the experience can be emotionally significant. It is worth having a direct conversation with a healthcare provider or reproductive endocrinologist about what a specific result actually means for your individual situation, rather than relying on internet comparisons or consumer testing ranges.
Research on direct-to-consumer fertility testing has found that results delivered without clinical context can generate significant anxiety and, in some cases, lead to premature decisions about fertility treatment that may not reflect the full picture. Seeking interpretation from a reproductive specialist who can integrate AMH into a complete assessment is strongly advisable. The emotional dimensions of navigating fertility testing after 35 are significant, and engaging with support resources for the TTC journey alongside clinical consultations can be valuable.
Low AMH: What It Means and What It Doesn’t
A lower-than-average AMH result for a given age does not mean pregnancy is impossible, that natural conception will not occur, or that IVF is the only path forward. It is one data point that, in context, may suggest the ovarian reserve is on the lower side of typical for that age group. What that means practically depends on many factors, including the individual’s overall health, other fertility assessment results, and their specific reproductive goals and circumstances.
A reproductive endocrinologist is best positioned to interpret AMH in context and to advise on whether any change in timing, approach, or further evaluation is warranted based on the full clinical picture.
Frequently Asked Questions
Should I get AMH testing if I’m over 35 and planning to try to conceive?
This is worth discussing with your healthcare provider. Some reproductive specialists recommend baseline fertility testing — including AMH — for women over 35 who are planning to conceive, to help inform timing and any decisions about seeking specialist input. Others suggest beginning to try naturally first and pursuing testing if conception has not occurred after six months. There is no universally right answer, and your healthcare provider can help guide the decision based on your individual circumstances.
What is considered a “normal” AMH level for a 37-year-old?
AMH reference ranges vary between laboratories, and what is “normal” is typically expressed as a range by age group. Rather than comparing to a single number, it is most useful to have your result interpreted by a healthcare provider who can contextualize it alongside your antral follicle count, cycle history, and other clinical information. Population averages are reference points, not fixed criteria.
Can AMH levels change over time?
AMH levels generally decline with age as part of normal ovarian aging. Unlike other hormones, AMH is relatively stable across the menstrual cycle and does not typically show major fluctuations from month to month, though some variation in laboratory measurements can occur. Significant changes in AMH over a short period may warrant discussion with a healthcare provider.
Does a high AMH guarantee I’ll have no fertility challenges?
No. Higher AMH suggests a larger ovarian reserve, but it does not guarantee egg quality, successful fertilization, or a straightforward conception. Egg quality — which plays a significant role in conception and healthy pregnancy outcomes — is not assessed by AMH. Other factors including overall reproductive health, partner fertility, and uterine factors also influence conception outcomes.
Key Takeaways
- AMH is a marker of ovarian reserve (egg quantity), not egg quality — and egg quality is considered the more significant factor in conception outcomes after 35.
- AMH is most directly useful in IVF planning, where it informs expectations about ovarian response to stimulation.
- For women trying to conceive naturally, AMH has limited predictive value for individual outcomes — many women with lower AMH conceive without intervention.
- AMH results are best interpreted by a reproductive specialist alongside antral follicle count, cycle history, and other clinical information.
- Direct-to-consumer AMH testing without clinical support can generate unhelpful anxiety — seeking interpretation from a healthcare provider is strongly advisable.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.